Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunomedics, known for development of monoclonal antibody-based products, has reported efficacy of subcutaneous injections of low-dose Veltuzumab in producing high rates of response in relapsed immune thrombocytopenia (ITP).
Subscribe to our email newsletter
Veltuzumab, a humanized anti-CD20 antibody was constructed using the same human donor frameworks as epratuzumab.
The results demonstrated that two doses of veltuzumab produced an overall objective response (OR) rate of 67%, including an 18% durable complete response (CR) rate, in 39 ITP patients.
Responses were observed for all doses tested, including the lowest dose at 80 mg, irrespective of the route of administration, history of splenectomy or prior use of rituximab.
Immunomedics president and CEO Cynthia L Sullivan said the results showed that subcutaneous injection of veltuzumab is convenient, well tolerated and active in relapsed ITP.
"We continue to enroll patients into 2 of the 3 subcutaneous dose levels and expect to complete enrollment into this first study in ITP in 2012," Sullivan added.